Research Unit for Rare Diseases, Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic; Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, Prague 128 08, Czech Republic; UCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Research Unit for Rare Diseases, Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic.
Am J Hum Genet. 2018 Mar 1;102(3):447-459. doi: 10.1016/j.ajhg.2018.02.002.
In a large family of Czech origin, we mapped a locus for an autosomal-dominant corneal endothelial dystrophy, posterior polymorphous corneal dystrophy 4 (PPCD4), to 8q22.3-q24.12. Whole-genome sequencing identified a unique variant (c.20+544G>T) in this locus, within an intronic regulatory region of GRHL2. Targeted sequencing identified the same variant in three additional previously unsolved PPCD-affected families, including a de novo occurrence that suggests this is a recurrent mutation. Two further unique variants were identified in intron 1 of GRHL2 (c.20+257delT and c.20+133delA) in unrelated PPCD-affected families. GRHL2 is a transcription factor that suppresses epithelial-to-mesenchymal transition (EMT) and is a direct transcriptional repressor of ZEB1. ZEB1 mutations leading to haploinsufficiency cause PPCD3. We previously identified promoter mutations in OVOL2, a gene not normally expressed in the corneal endothelium, as the cause of PPCD1. OVOL2 drives mesenchymal-to-epithelial transition (MET) by directly inhibiting EMT-inducing transcription factors, such as ZEB1. Here, we demonstrate that the GRHL2 regulatory variants identified in PPCD4-affected individuals induce increased transcriptional activity in vitro. Furthermore, although GRHL2 is not expressed in corneal endothelial cells in control tissue, we detected GRHL2 in the corneal "endothelium" in PPCD4 tissue. These cells were also positive for epithelial markers E-Cadherin and Cytokeratin 7, indicating they have transitioned to an epithelial-like cell type. We suggest that mutations inducing MET within the corneal endothelium are a convergent pathogenic mechanism leading to dysfunction of the endothelial barrier and disease.
在一个具有捷克血统的大家庭中,我们将常染色体显性遗传角膜内皮营养不良、后多形性角膜营养不良 4(PPCD4)的基因座定位于 8q22.3-q24.12。全基因组测序在该基因座内发现了一个独特的变异(c.20+544G>T),位于 GRHL2 的内含子调控区域。靶向测序在另外三个以前未解决的 PPCD 受影响的家族中发现了相同的变异,包括一个新生的发生,表明这是一个反复出现的突变。在无关的 PPCD 受影响的家族中,GRHL2 的内含子 1 中还发现了另外两个独特的变异(c.20+257delT 和 c.20+133delA)。GRHL2 是一种转录因子,可抑制上皮细胞向间充质转化(EMT),是 ZEB1 的直接转录抑制剂。导致单倍不足的 ZEB1 突变导致 PPCD3。我们之前发现 OVOL2 启动子突变是 PPCD1 的原因,OVOL2 是一种通常不在角膜内皮中表达的基因。OVOL2 通过直接抑制 EMT 诱导转录因子(如 ZEB1)来驱动间充质向上皮转化(MET)。在这里,我们证明在 PPCD4 受影响的个体中鉴定的 GRHL2 调节变异在体外诱导增加的转录活性。此外,尽管 GRHL2 在对照组织的角膜内皮细胞中不表达,但我们在 PPCD4 组织的角膜“内皮”中检测到了 GRHL2。这些细胞也对上皮标志物 E-Cadherin 和 Cytokeratin 7 呈阳性,表明它们已转变为类似上皮的细胞类型。我们认为,在内皮细胞中诱导 MET 的突变是导致内皮屏障功能障碍和疾病的收敛性致病机制。